- 関
- microprolactinoma、PRL-secreting pituitary adenoma、prolactin-secreting pituitary adenoma、prolactinoma
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 乳腺刺激腺腫およびその他の原因による高プロラクチン血症の治療 treatment of hyperprolactinemia due to lactotroph adenoma and other causes
- 2. 高プロラクチン血症の臨床症状および診断 clinical manifestations and diagnosis of hyperprolactinemia
- 3. 妊娠中の乳腺刺激腺腫（プロラクチン産生腫瘍）の管理 management of lactotroph adenoma prolactinoma during pregnancy
- 4. 高プロラクチン血症の原因 causes of hyperprolactinemia
- 5. 鞍部腫瘤の原因、症状、および評価 causes presentation and evaluation of sellar masses
English Journal
- Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
- Rastogi A1, Bhadada SK1, Bhansali A1.
- Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.Gynecol Endocrinol.2016 Dec 2:1-4. [Epub ahead of print]
- Hyperprolactinemia and prolactinomas cause infertility in significant number of women. But, pregnancy may lead to post-partum remission of hyperprolactinemia. The data on pregnancy and tumor outcome in women with macroprolactinoma conceiving on Cabergoline (CAB) therapy is increasing but still less
- PMID 27908214
- Long-term outcome of macroprolactinomas.
- Képénékian L1, Cebula H2, Castinetti F3, Graillon T4, Brue T3, Goichot B5.
- Annales d'endocrinologie.Ann Endocrinol (Paris).2016 Dec;77(6):641-648. doi: 10.1016/j.ando.2016.07.004. Epub 2016 Sep 15.
- OBJECTIVE: Management of macroprolactinomas has dramatically changed in recent decades, from surgical to medical treatment as first-line therapy, with the development of dopamine agonists (DA). But few data exist on the long-term outcome of these patients.PATIENTS AND METHODS: Retrospective descript
- PMID 27641080
- Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
- Sala E1, Bellaviti Buttoni P2, Malchiodi E2, Verrua E2, Carosi G2, Profka E2, Rodari G2, Filopanti M2, Ferrante E2,3, Spada A2, Mantovani G2.
- Journal of endocrinological investigation.J Endocrinol Invest.2016 Dec;39(12):1377-1382. Epub 2016 May 31.
- BACKGROUND: The optimal duration of cabergoline (CAB) treatment of prolactinomas that minimizes recurrences is not well established. 2011 Endocrine Society Guidelines suggested that withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor reduction.MATERI
- PMID 27245604
Japanese Journal
- Macroprolactinoma に対するカベルゴリン治療 : その効果判定と3T MRI画像所見
- CI研究 : progress in computed imaging 31(4), 241-246, 2010-03-31
- NAID 10026325400
- Cabergoline Effectively Induced Remission of Prolactinoma in a 9-year-old Japanese Boy
- Clinical pediatric endocrinology 18(2), 65-72, 2009-04-01
- NAID 10031199593
- A Case of Macroprolactinoma with Subclinical Growth Hormone Production
- Endocrine journal 49(1), 41-47, 2002-02
- NAID 10007868723
Related Pictures
★リンクテーブル★
| リンク元 | 「prolactin-secreting pituitary adenoma」「PRL-secreting pituitary adenoma」「マクロプロラクチノーマ」「microprolactinoma」 |
「prolactin-secreting pituitary adenoma」
[★] プロラクチン産生下垂体腺腫、プロラクチン分泌下垂体腺腫、プロラクチノーマ
「PRL-secreting pituitary adenoma」
[★] プロラクチン産生下垂体腺腫、プロラクチン分泌下垂体腺腫